The 2016-2017 Leadership Development Program has 16 participants from various practice settings, subspecialties, and geographic locations.
Manmeet S. Ahluwalia MD, FACP
Discipline/Focus: Medical Oncology/Brain Tumors
Manmeet S. Ahluwalia MD, FACP, is a neuro-oncologist and Associate Professor of Medicine at Cleveland Clinic Lerner College of Medicine. He is the initial recipient of the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology at the Cleveland Clinic where he serves as the Director of the Brain Metastases Research program and Head of operations at the Burkhardt Brain Tumor and Neuro-Oncology Center. He is engaged in clinical investigation in National Cancer Institute supported consortia—NRG Oncology Group and the American Brain Tumor Consortium (ABTC). He also serves as Principal Investigator, leading several clinical trials involving new-targeted therapies as well as immunotherapeutic approaches. He has been the recipient of prestigious awards including Leading in Healthcare at the Cleveland Clinic and the NCI/ CTEP Award for Clinical trial development in ABTC.
Dr. Ahluwalia is actively involved in the Society for Neuro-Oncology (SNO) where he has served as the Chair of the Membership Committee (2013- 2015) and as a member of the Guidelines Committee. He is the Co-Chair of the Education Day of SNO Annual Meeting, 2016. He serves as the Chair of the Scientific Review Committee of the International Gamma Knife Research Foundation (IGKRF). In addition, he is the Chair of the ASCO Cancer Education Committee for Central Nervous system (CNS) track for 2015-16 and has served as a liaison on the ASCO Scientific Planning Committee.
Julie E. Bauman, MD, MPH
Discipline/Focus: Medical Oncology/Head and Neck Cancer
Julie E. Bauman, MD, MPH, is an Associate Professor of Medicine at the University of Pittsburgh Cancer Institute (UPCI) and Co-Leader of the UPCI Head and Neck Cancer Program. Dr. Bauman graduated with a dual MD/MPH degree from Tufts University in 1999, earning election to AOA, the William Dameshek Award and the MD/MPH Academic Achievement Award. She completed Internal Medicine residency at the University of Utah and Medical Oncology fellowship at the University of Washington.
Dr. Bauman’s overarching vision is to conduct rigorous, biomarker-driven clinical trials to improve clinical outcomes in patients with head and neck cancer. Dr. Bauman co-leads the chemoprevention project for the UPCI Head and Neck SPORE, and is PI of a V Foundation Translational Grant evaluating the driver properties of PIK3CA mutations in the context of HPV infection. In 2011, Dr. Bauman received the NCI Clinical Investigator Team Leadership Award. She serves on the Head and Neck Core Committees of ECOG/ACRIN and the NRG, and the Recurrent/Metastatic Task Force of the NCI Head and Neck Steering Committee.
Robert J. Canter, MD
Discipline/Focus: Surgical Oncology/Soft tissue Sarcoma
Robert J. Canter, MD, obtained his undergraduate degree from Princeton University and his medical degree from the University of Pennsylvania. He completed general surgery training at the Hospital of the University of Pennsylvania followed by subspecialty training in Surgical Oncology at the Memorial Sloan Kettering Cancer Center.
In 2007, he joined the faculty of the University of California Davis School of Medicine in the Department of Surgery, Division of Surgical Oncology. Dr. Canter’s research focuses on sarcoma cancer stem cells as a mechanism of resistance to standard anti-proliferative anti-cancer therapies. He is studying natural killer (NK) cellular immunotherapy as a mechanism to target the cancer stem cell population following standard cancer treatments such as radiotherapy. His goal is to translate these studies to early phase clinical trials for canine and human patients with advanced bone and soft tissue sarcomas. He currently holds the title of Associate Professor.
Suzanne Cole, MD, FACP
Discipline/Focus: Hematology & Medical Oncology (General)
Suzanne Cole, MD, FACP, is a community based Hematologist & Medical Oncologist at Mercy Hospital in Oklahoma City. Dr. Cole completed her fellowship in Hematology/Oncology at UT MD Anderson Cancer Center in 2010. She is passionate about coordinating care between her community hospital, University hospital, and regional NCI-designated cancer center to ensure her patients receive the highest level of expertise, while choosing to remain close to home for their treatment.
Dr. Cole has a clinical interest in genitourinary oncology and has made an alliance with the Urology Department at OU Medical Center, attending their GU tumor board and shepherding patients across the community and university divide, to allow her patients to benefit from the best surgical options. In an attempt to streamline patient care across two hospital systems in Oklahoma City, she created a multidisciplinary Lung Cancer Case Conference that she is actively working to transform into a comprehensive multidisciplinary clinic. Dr. Cole was elected Fellow of the American College of Physicians in 2015 and serves on the ACP Early Career Physician Committee. Dr. Cole was featured in the Ken Burns PBS documentary, "Cancer: The Emperor of All Maladies." In an unprecedented attempt to capture authentic end-of-life care conversations, Dr. Cole allowed cameras to go behind closed doors to film these difficult moments with her patients facing terminal disease.
Neelima Denduluri, MD
Discipline/Focus: Medical Oncology/Breast Cancer
Neelima Denduluri, MD, is a medical oncologist with Virginia Cancer Specialists (VCS), an affiliate of the US Oncology Network (USON). Dr. Denduluri earned her medical degree from the Louisiana State University Medical Center, where she served as President of the American Medical Student Association. She completed her residency at Georgetown University Medical Center, where she currently serves as Clinical Assistant Professor. Dr. Denduluri completed her fellowship at the National Cancer Institute, and served as Assistant Clinical Investigator and Staff Physician before joining VCS.
Dr. Denduluri serves as Associate Chair of the US Oncology Breast Cancer Research Committee; Chair-Elect for the ASCO Clinical Practice Guidelines Committee; and Cancer Committee Chairman at Virginia Hospital Center. She has served as principal investigator in many clinical trials, with a special interest in breast cancer. Dr. Denduluri’s publications have been presented at various national meetings, including ASCO and the San Antonio Breast Cancer Symposium.
Rachel Freedman, MD, MPH
Discipline/Focus: Medical Oncology/Breast Cancer
Rachel Freedman, MD, MPH, received her BS in Biology from the University of Michigan in 1999, her MD from Georgetown University School of Medicine in 2003, and a Master in Public Health degree at Harvard School of Public Health in 2008. In 2006, she completed internal medicine residency at Beth Israel Deaconess Medical Center (Boston, MA) and then completed her medical oncology fellowship at Dana-Farber Cancer Institute (Boston, MA) in 2009. She has been on staff at Dana-Farber since that time. Dr. Freedman is a clinical researcher and also practices medical oncology in the Breast Oncology Center at Dana-Farber.
She is Associate Medical Director of her clinical practice and an Assistant Professor of Medicine at Harvard Medical School. She also practices at Dana-Farber’s community outreach clinic, Whittier Street Health Center (Roxbury, MA). Her research interests include disparities in breast cancer care, the care of older patients with breast cancer, and clinical trial development. She is honored and excited to be a part of ASCO’s Leadership Development Program!
Leora Horn, MD, MSc
Discipline/Focus: Medical Oncology/Lung Cancer
Leora Horn, MD, MSc, is an Associate Professor of Medicine and the Clinical Director of the Thoracic Oncology Research Program at Vanderbilt Ingram Cancer Center (VICC) in Nashville TN. She is also the Assistant Vice Chancellor for Faculty Development at Vanderbilt University Medical Center. Her clinical practice focuses on the care of patients with lung cancer.
She is an active member of the Eastern Cooperative Oncology Group, International Association for the Study of Lung Cancer, and the American Society of Clinical Oncology. She has over 70 publications including in the New England Journal of Medicine, Nature Medicine, and Journal of Clinical Oncology. In the last five years, she has been among the top 5 in accrual to clinical trials at VICC where she has a focus on clinical trials with targeted therapies and immunotherapy as well as small cell lung cancer. Dr. Horn works closely with many collaborators at VICC translating laboratory findings into clinical trials for patients with lung cancer.
Benjamin Levy, MD
Discipline/Focus: Thoracic Medical Oncology
Benjamin Levy, MD, is Assistant Professor at the Icahn School of Medicine and currently the Medical Director of Thoracic Oncology for Mount Sinai Health Systems. In addition, he serves as Associate Director of the Cancer Clinical Trials Office (CCTO) for Mount Sinai Hospital. Dr. Levy is a physician scientist who is currently leading global immunotherapy trials evaluating checkpoint point inhibitors with novel combination strategies. He also remains interested in the therapeutic value of repurposed therapies like metformin in lung cancer and the genetic alterations that predict sensitivity to such agents.
Dr. Levy has played an integral role on several ASCO committees and most recently serves as Associate Editor for the ASCO University Committee where he helps develop educational web based content for oncologists across the country. He recently served on the editorial board for the Journal of Clinical Oncology and serves as an ad hoc reviewer for other journals including Clinical Lung Cancer and The Oncologist. It addition to his ASCO commitments, Dr. Levy serves on the ALLIANCE Respiratory Committee and on the IASLC Staging Committee and Career Development & Fellowship Committee.
Gilberto Lopes, MD, MBA
Discipline/Focus: Pharmacoeconomics; Clinical trial development in Lung, GI and Breast cancers
Gilberto Lopes, MD, MBA, is Chief Medical and Scientific Officer for the Oncoclinicas Group, the largest Oncology provider in Latin America with 34 clinics and more than 290 physicians. He holds a concomitant position as faculty member at the Johns Hopkins University in the United States. Dr. Lopes has published more than 100 papers and book chapters in journals such as the Journal of Clinical Oncology, Cancer, Nature Reviews, and Lancet Oncology. His main areas of interest are drug development, health economics, policy and access to cancer drugs in low and middle income countries.
At ASCO, Dr. Lopes has volunteered as committee member and as Associate Editor for ASCO University and the Journal of Global Oncology. He has also served as an expert for the International Atomic Energy Agency and the World Health Organization in official missions. In addition, he has advised governments, professional societies, and industry partners on issues related to cancer control and treatment.
Bradley McGregor, MD
Discipline/Focus: Cancer Genetics
Bradley McGregor, MD, is a medical oncologist at the Dana-Farber Cancer Institute in Boston, MA. He completed his undergraduate and medical education at Tufts University before joining the United States Air Force where he underwent postgraduate training in San Antonio, Texas. Dr. McGregor, attaining the rank of Lieutenant Colonel, has provided oncologic care to the US Military, their dependents, retirees, and veterans while serving as faulty for the Uniformed Services University of the Health Sciences and as the Transitional Year Program director the past 2 years.
He received training in the City of Hope Intensive Course in Cancer Genetics Risk Assessment and is one of two military oncologists providing cancer genetics counseling. In 2013 he was deployed to Afghanistan where he mentored physicians at Kabul National Military Hospital. Dr. McGregor will separate from the Air Force in 2016 and move back to the Northeast. He is married to PeiChun McGregor, MD, and they have two children, Emma and Luke.
Sumanta Kumar Pal, MD
Discipline/Focus: Genitourinary Cancers: Prostate, Bladder and Kidney
Sumanta Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers. He is the Co-director of City of Hope's Kidney Cancer Program and head of the kidney and bladder cancer disease team at the institution.
Dr. Pal entered medical school at UCLA at the age of 17. After completing his residency training, he completed a fellowship program in medical oncology at City of Hope where he has remained on faculty since 2009. To date, he has published over 150 peer-reviewed articles in prominent journals including The Journal of Clinical Oncology, Lancet Oncology, and European Urology.
Dr. Pal holds patents for new prostate cancer drugs currently under development and maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the west coast. He developed an integrated program that focuses on collaborative research across multiple departments, including the Beckman Research Institute and Department of Surgery, to discover novel therapeutic approaches. He works to push the boundaries of personalized medicine, with several seminal publications that describe unique therapeutic targets in rare genitourinary cancers. He has received grants from the National Institute of Health and multiple other leading entities in support of his formidable research.
Rodney P. Rocconi, MD
Discipline/Focus: Gynecologic Oncology
Rodney P. Rocconi, MD, currently serves as Professor & Chief of Gynecologic Oncology and as Associate Director for Clinical Research at the University of South Alabama Mitchell Cancer Institute in Mobile, Alabama. He has a productive research career credited with over 100 presentations at national meetings and over 80 publications. His research interests include understanding the molecular mechanisms of chemoresistance in ovarian cancer stem cells, as well as genetic contributions of racial healthcare disparities in gynecologic malignancies.
His research program is supported by multiple NIH/NCI and foundation grants. He has been recognized for his work as a recipient of the Gynecologic Cancer Foundation Ovarian Cancer Research Award, the Gynecologic Oncology Group Young Investigator Research Award, and as an invited Associate Member of the NCI Early Detection Research Network. These experiences have allowed him to serve on national leadership roles in the Society of Gynecologic Oncology as well as chair certain DOD Ovarian Cancer Research Program sections.
Tiffany A. Traina, MD
Discipline/Focus: Medical Oncology/Breast & TNBC
Tiffany A. Traina, MD, is an Associate Attending Physician and Clinical Director of the Breast Medicine Service at Memorial Sloan Kettering. She serves as the Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is also Assistant Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancers, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor in breast cancers.
Dr. Traina serves on the ASCO Scientific Program Committee for the Triple Negative Breast Cancer/Cytotoxics/Local Therapy track and is a member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. Her research efforts have earned her the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation. She has received teaching awards from Memorial Sloan Kettering and Weill Cornell Medicine and the 2014 Hero Award from the Triple Negative Breast Cancer Foundation.
Glen Weiss, MD, MBA
Discipline/Focus: Drug Development/Thoracic Oncology
Glen Weiss, MD, MBA, serves as the Director of Clinical Research and Phase I & II Clinical Trials at Cancer Treatment Centers of America at Western Regional Medical Center. He has been involved with numerous clinical trials with investigational agents, a few of which have gone on to receive FDA approval. He is a Clinical Associate Professor at the Translational Genomics Research Institute (TGen) in Phoenix and a Clinical Associate Professor at the University of Arizona College of Medicine-Phoenix.
Dr. Weiss earned a medical degree from Sackler School of Medicine in Tel Aviv, Israel, completed an internal medicine residency at SUNY-Downstate in Brooklyn, followed by a hematology/medical oncology fellowship at the University of Colorado Health Sciences Center, serving as the Chief Fellow in his final year. He has published over 200 peer-reviewed articles and abstracts in journals such as New England Journal of Medicine and Journal of Clinical Oncology. Dr. Weiss is proud to have mentored a number of students over the years on laboratory or clinical research projects.
Karen Winkfield, MD, PhD
Discipline/Focus: Radiation Oncology/ Hematologic Malignancies & Breast
Karen Winkfield, MD, PhD, is a Radiation Oncologist at the Wake Forest Comprehensive Cancer Center, specializing in the use of radiation therapy in the treatment of hematologic malignancies and breast cancer. Her research is focused on the design and implementation of programming to reduce sociocultural and economic barriers that contribute to disparate health outcomes for blacks. Her goal is to empower the black community with knowledge and encourage policymakers to invest in initiatives designed to eliminate inequities in the health care delivery system.
Dr. Winkfield is Co-Founder and Director of the Association of Black Radiation Oncologists. She serves as Chair of the Health Access and Training Subcommittee for the American Society of Radiation Oncologists (ASTRO) and is Chair-Elect of the American Society of Clinical Oncology (ASCO) Health Disparities Committee.
Eddy S. Yang, MD, PhD
Discipline/Focus: Radiation Oncology/ Prostate, Breast, Head and Neck Cancers, Translational Research
Eddy S. Yang, MD, PhD, received his MD and PhD from the University of Miami School of Medicine and continued post-graduate training in the Department of Radiation Oncology at Vanderbilt University as a Holman Pathway Resident Research Scholar. He subsequently joined the University of Alabama at Birmingham (UAB) in 2010 and is an Associate Professor of radiation oncology; cell, developmental, and integrative biology; and pharmacology and toxicology at UAB. Dr. Yang is the inaugural holder of the ROAR Southeast Cancer Foundation Endowed Chair and is a physician scientist who aims to translate basic research findings into the clinic by exploiting tumor driver pathways as part of therapeutic strategies against cancer.
He also has a strong interest in personalized medicine and serves as the Director of the UAB Molecular Tumor Board and is part of the UAB Personalized Medicine Integration team. His research has been supported by various organizations, including the National Cancer Institute, Department of Defense, Susan G. Komen Foundation, Sidney Kimmel Foundation, AACR, Gabrielle’s Angel Foundation, and others. Ultimately by understanding the drivers of cancer, he aims to not only improve patient outcomes, but, more importantly, preserve patient quality of life.